| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2036.2010.04235.X |
| P8608 | Fatcat ID | release_q6dle3fpibbkxf3uyqck7dxk5y |
| P932 | PMC publication ID | 2923484 |
| P698 | PubMed publication ID | 20070284 |
| P5875 | ResearchGate publication ID | 41011709 |
| P50 | author | Jules Dienstag | Q69897087 |
| P2093 | author name string | M G Ghany | |
| R K Sterling | |||
| A M Di Bisceglie | |||
| HALT-C Trial Group | |||
| T R Morgan | |||
| R J Fontana | |||
| H L Bonkovsky | |||
| H-Y Kim | |||
| K K Snow | |||
| P2860 | cites work | Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon | Q27487518 |
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. | Q31987662 | ||
| The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity | Q32043227 | ||
| Pathogenesis, natural history, treatment, and prevention of hepatitis C. | Q33841882 | ||
| Transection of the oesophagus for bleeding oesophageal varices | Q34211834 | ||
| Fatigue, depression and chronic hepatitis C infection | Q34554894 | ||
| Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin | Q34681541 | ||
| Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis | Q36015711 | ||
| Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment | Q36080601 | ||
| Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan | Q36497183 | ||
| Quality of life in hepatitis C. | Q36566758 | ||
| Overview of research on health-related quality of life in patients with chronic liver disease. | Q36893417 | ||
| Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. | Q39136657 | ||
| The treatment of chronic viral hepatitis | Q41332870 | ||
| Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients | Q42671117 | ||
| Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients | Q42993749 | ||
| Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection | Q43036938 | ||
| The effect of early virological response in health-related quality of life in HCV-infected patients | Q43047616 | ||
| Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin | Q43047845 | ||
| Fatigue in patients with chronic hepatitis C. | Q43549742 | ||
| Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. | Q43746149 | ||
| Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. | Q44437005 | ||
| Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
| Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection | Q45393611 | ||
| Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life | Q45415714 | ||
| Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis | Q45758628 | ||
| Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. | Q45968545 | ||
| The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. | Q46161384 | ||
| Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life | Q46970292 | ||
| Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. | Q48011329 | ||
| Health-related quality of life predicts mortality in patients with advanced chronic liver disease | Q48405701 | ||
| Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. | Q48849538 | ||
| Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. | Q50580484 | ||
| Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. | Q50851322 | ||
| Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. | Q51099755 | ||
| Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis. | Q51877371 | ||
| Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. | Q51935294 | ||
| Determinants of health-related quality of life in patients with chronic liver diseases. | Q51942517 | ||
| Goodness-of-fit in generalized nonlinear mixed-effects models. | Q52303453 | ||
| Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. | Q53394448 | ||
| Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. | Q53450437 | ||
| Health assessment for chronic HCV infection: results of quality of life. | Q53612057 | ||
| Quality of life and cognitive function in hepatitis C at different stages of liver disease | Q73695589 | ||
| Biopsychosocial predictors of fatigue in chronic hepatitis C | Q81633191 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic hepatitis | Q62019625 |
| P304 | page(s) | 719-734 | |
| P577 | publication date | 2010-01-12 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C | |
| P478 | volume | 31 |
| Q26767084 | Extrahepatic manifestations of chronic hepatitis C virus infection |
| Q45934115 | Fatigue and physical activity levels in patients with liver cirrhosis. |
| Q36310606 | Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study |
| Q96685843 | Impact of chronic HCV treatment on quality of life of patients with metabolic disorders in context of immunological disturbances |
| Q56917730 | Influence of healthcare-associated factors on the efficacy of hepatitis C therapy |
| Q91979716 | Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: A meta-analysis |
| Q34511200 | No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C |
| Q39002714 | Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues |
| Q33694159 | Processes to manage analyses and publications in a phase III multicenter randomized clinical trial |
| Q47548382 | Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. |
| Q36063808 | Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort |
| Q37179504 | Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients. |
Search more.